JMS Co

JMS Co Receivables

The Accounts Receivable of JMS Co (7702.T) as of Nov 3, 2026 is 17.35 B JPY. In the previous year, Accounts Receivable was 16.81 B JPY — a change of 3.22% (higher).

Receivables

17.35 BJPY

YoY

3.22%

Last updated:

Accounts Receivable of JMS Co is 2025 17.35 B JPY. Accounts Receivable of JMS Co was 2024 16.81 B JPY. It decreases by 3.22% higher compared to the previous year.

The JMS Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
16.42 B JPY
Jan 1, 2019
15.81 B JPY
Jan 1, 2020
15.65 B JPY
Jan 1, 2021
16.39 B JPY
Jan 1, 2022
14.49 B JPY
Jan 1, 2023
15.32 B JPY
Jan 1, 2024
16.81 B JPY
Jan 1, 2025
17.35 B JPY
The JMS Co Receivables history
YEARReceivablesYoY
17.35 BJPY+3.22%
16.81 BJPY+9.71%
15.32 BJPY+5.72%
14.49 BJPY-11.59%
16.39 BJPY+4.69%
15.65 BJPY-1.01%
15.81 BJPY-3.71%
16.42 BJPY+7.49%
15.28 BJPY-2.28%
15.64 BJPY-3.12%
16.14 BJPY-0.40%
16.20 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JMS Co Stock analysis

What does JMS Co do? JMS Co., Ltd. generates revenue through the manufacture, sale, export, and import of medical devices and pharmaceuticals across its five geographical segments: Japan, Singapore, China, Philippines, and Germany. The company offers a range of products including infusion and nutrition products, dialysis products, surgery products, blood and cell products, and other related items. Key products such as infusion & transfusion sets, syringe pumps, surgical gowns, dialysis kits, peritoneal dialysate, microcatheters, and blood bags are sold to healthcare providers and institutions within these regions. The firm also provides maintenance services and other related services as part of its product portfolio. The company's primary customers are healthcare providers and institutions in Japan, Singapore, China, Philippines, and Germany, where it operates through its five geographical segments. These customers purchase medical equipment and drugs, including specific items like infusion & transfusion sets, dialysis kits, and surgical gowns. The firm's product lines are tailored to meet the needs of hospitals, clinics, and other medical facilities across its operational regions. JMS Co., Ltd. focuses on manufacturing and selling medical equipment and drugs, with a strong emphasis on products such as infusion & transfusion sets, syringe pumps, surgical gowns, and dialysis kits. The company's revenue streams are driven by the sale of these products and the provision of maintenance services. Its geographical segments ensure a diversified market presence, allowing it to serve various healthcare sectors in different countries. JMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JMS Co stock

Accounts Receivable of JMS Co is 17.35 B JPY in 2025.

Accounts Receivable of JMS Co changed from 16.81 B JPY to 17.35 B JPY, representing a 3.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable JMS Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's JMS Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — JMS Co

All Key Metrics — JMS Co